Zinbryta (daclizumab) / Biogen, AbbVie - LARVOL DELTA

Daclizumab enhances aGVHD prophylaxis by modulating T-cell polarization while preserving the graft-versus-lymphoma effect (ASH 2025) - "Our prior clinical data showed that adding Daclizumab, an anti-CD25 monoclonal antibody, to standard prophylaxis (Mycophenolate mofetil/Tacrolimus/Methotrexate) significantly reduced grade 3–4 aGvHD incidence in thalassemia patients undergoing alternative donor HSCT. Daclizumab enhances aGvHD prophylaxis by modulating T-cell polarization—favoring Th2/Treg balance and reducing cytotoxicity—while preserving graft-versus-lymphoma effects. These findings support anti-CD25 antibodies as a promising strategy to optimize immune tolerance and anti-tumor efficacy post-transplantation."

Acute Graft versus Host Disease • Bone Marrow Transplantation • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Lymphoma • CD4 • CD69 • CD8 • GZMB • IFNG • IL17A • IL2 • IL4 • PRF1

Humanized anti-CD25 monoclonal antibody for previously treated hemophagocytic lymphohistiocytosis in adults: A prospective, open-label clinical trial (ASH 2025) - "Anti-CD25 mAb demonstrates established efficacy in treatingmultiple sclerosis and preventing post-transplant rejection, with a favorable toxicity profile.This trial evaluated the efficacy and safety of anti-CD25 mAb (Daclizumab) in patients with HLH who hadnot responded to previous dexamethasone-based therapy. It had low toxicityand was well tolerated. This novel treatment is promising and merits further investigation in a largercohort."

Clinical • Bone Marrow Transplantation • CNS Disorders • Epstein-Barr Virus Infections • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Lymphoma • Multiple Sclerosis • Rare Diseases • Respiratory Diseases • Transplant Rejection • IL2

Targeted Therapies and Pharmacologic Advances in Mucous Membrane Pemphigoid: A Comprehensive Review. (PubMed, Dermatol Pract Concept) - "Considering the severity of the condition, progressive fibrosis, and resistance to therapy, more research is required in relation to the pathogenesis of MMP and the efficacy and safety profile of novel pharmacological options. Pharmacological agents should provide the achievement and maintenance of remission with minimal adverse effects. A broader spectrum of pharmacological agents will allow a personalized approach and more alternatives, in particular for recalcitrant cases, failure of the previous therapy, and in patients with MMP and malignancy."

Journal • Review • Dermatology • Fibrosis • Immunology • Infectious Disease • Oncology

Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Related Haploidentical Donor and Unrelated Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China (ASH 2023) - "This study aimed to investigate whether Daclizumab at a dose of 1 mg/Kg on days +7, +14, +28 and +42 reduced GVHD plus standard GVHD prophylaxis (tacrolimus [FK506] plus methotrexate [MTX] and mycophenolate mofetil [MMF]) in TM patients with HID-HSCT or MUD-HSCT. The results of our study analysis suggest that Daclizumab at a dose of 1 mg/kg on days +7, +14, +28 and +42 provides clinically meaningful benefits when added to standard GVHD prophylaxis in TM patients undergoing haploidentical donor and unrelated donor transplantation, including decrease in the incidence rate of aGVHD without sever infection and transplant-related complications. Four doses of Daclizumab should be included in the GVHD prophylaxis of patients with thalassemia major selected for related haploidentical donor and unrelated donor transplantation."

Retrospective data • Acute Graft versus Host Disease • Beta-Thalassemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Genetic Disorders • Graft versus Host Disease • Immunology • Infectious Disease • Respiratory Diseases • Transplantation

Comparative Oncology: Cross-Sectional Single-Cell Transcriptomic Profiling of the Tumor Microenvironment Across Seven Human Cancers. (PubMed, Cancers (Basel)) - "The competitive receptor ACKR1 was minimally expressed on endothelial cells, consistent with PDAC hypo-vascularity...Differential interactions and the presence of "dominant signaling cell populations " with dominant outgoing signals may underlie the heterogeneity in tumor aggressiveness across these cancers. Comparative scRNA-seq analysis of multiple cancers reveals distinct tumor phenotypes and cell-cell communication patterns, offering insights into the molecular architecture of human solid tumors."

Biomarker • Journal • Breast Cancer • Colorectal Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Hepatocellular Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Squamous Cell Carcinoma • Thyroid Gland Carcinoma • ACKR1 • CAFs • CXCR1 • CXCR2 • EPCAM • IGF1 • RGS5

Retrospective Comparison of Kidney Transplant Outcomes with Different Induction Methods and Maintenance Prednisone in Patients with Systemic Sclerosis (KIDNEY WEEK 2025) - "Results There were statistically significant worse outcomes in graft survival in SSc patients receiving induction therapy with alemtuzamab (AB), and thymo+basiliximab/thymo+daclizumab as well as with maintenance prednisone (MP). A 2005 case study documented two SRC recurrences, with the earlier event occurring in the patient on higher steroid doses. Hazard ratios of graft and patient survival comparing different induction methods and maintenance prednisone among SSc cohort"

Retrospective data • Immunology • Scleroderma • Systemic Sclerosis • Transplantation

Incidence, Patterns, and Outcomes of Fungal Infections in Patients with Graft Versus Host Disease Requiring Systemic Steroids Following Allogeneic Hematopoietic Cell Transplantation (ASH 2024) - "GVHD prophylaxis regimens included cyclosporine (n=116), tacrolimus or sirolimus (n=11), mycophenolate mofetil (MMF, n=125) and daclizumab (n=8). The pooled overall mortality rate due to IFIs was 23.6% (95% CI : 0.06-0.58, I2 =86.3%).CONCLUSION : Invasive fungal infections lead to significant mortality in patients with GVHD, with a higher incidence in acute GVHD as compared to chronic GVHD. Available literature is very heterogeneous, and our findings underscore the need for further research in this area."

Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Candidiasis • Chronic Graft versus Host Disease • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Respiratory Diseases • Transplantation

Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Alternative Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China (ASH 2024) - "This study aimed to investigate whether administering Daclizumab at a dose of 1 mg/kg on days +7, +14, +28, and +42, in addition to standard GvHD prophylaxis (tacrolimus [FK506], methotrexate [MTX], and mycophenolate mofetil [MMF]), reduces the incidence of GvHD in TM patients undergoing alternative donor HSCT...The conditioning regimen for all patients included busulfan (Bu, 1mg/kg i.v. 4x daily on days -9 to -6), cyclophosphamide (Cy, 50mg/kg i.v. once daily, days -5 to -2), fludarabine (Flu, 50mg/m² i.v. once daily from days -12 to -10), and anti-thymocyte globulin (ATG, 2.5mg/kg i.v. once daily, days -4 to -1). Sixty-six (39.05%) patients received letermovir in prophylaxis of cytomegalovirus (CMV) infection, including 65 in the Daclizumab group and 1 in the control group...The use of Daclizumab significantly reduced clinically relevant grade 3-4 aGvHD without increasing severe infections or transplant related complications, also improved post-transplant TGFS...."

Retrospective data • Acute Graft versus Host Disease • Beta-Thalassemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Transplantation

A Retrospective Comparison of Transplant Outcomes in Patients with and Without Systemic Sclerosis (ACR Convergence 2025) - "Induction immunosuppressive regimens analyzed included alemtuzumab, basiliximab/daclizumab, and combinations of thymoglobulin with either basiliximab or daclizumab, using thymoglobulin alone as the reference group... Using UNOS data from 211 SSc patients, we found statistically significant worse outcomes in both graft and patient survival when compared to matched controls in both DD and LD groups. Our findings align with prior UNOS-based studies which also reported lower graft survival rates in SSc transplant recipients. These poorer outcomes are likely multifactorial, potentially driven by SRC recurrence and multi-organ involvement."

Retrospective data • Immunology • Scleroderma • Systemic Sclerosis • Transplantation

A Retrospective Comparison of Transplant Outcomes with Different Induction Methods and Maintenance Prednisone in Systemic Sclerosis Patients (ACR Convergence 2025) - "The patients with no induction information were excluded. There were statistically significant worse outcomes in graft survival in SSc patients receiving induction therapy with alemtuzamab, and thymo+basiliximab/thymo+daclizumab as well as with maintenance prednisone. Different induction therapies in KT are chosen for either their safety profiles or immunosuppressive effects. Alemtuzumab a relatively newer agent, has recently been studied in a retrospective review of 225 SSc patients using data from 2012-2022 which demonstrated significantly poorer graft survival outcomes. This correlates with our findings for poor graft survival among SSc patients receiving alemtuzumab induction."

Retrospective data • Immunology • Scleroderma • Systemic Sclerosis • Transplantation

Single-cell Sequencing Analysis Reveals Cell Subtypes With High Expression of Coagulation Factor 3 and Their Possible Roles in Pancreatic Ductal Adenocarcinoma. (PubMed, Front Biosci (Landmark Ed)) - "The high expression of F3 in specific iCAF subtypes suggests a role in PDAC hypercoagulability and tumor progression. Targeting these iCAF subtypes could provide potential strategies for treating PDAC."

Biomarker • Journal • Cardiovascular • Hematological Disorders • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Thrombosis • CAFs

Extended window of relapse recovery in RRMS: an analysis of the DECIDE dataset. (PubMed, J Neurol Neurosurg Psychiatry) - "Most relapses (94.2%) recover, but the process of recovery can take up to 1 year and depends mostly on relapse severity. Our findings challenge the concept of 3-month and 6-month confirmed disability progression as reliable markers of permanent disability in RRMS trials. ACES occurs frequently and is associated with age."

Journal • CNS Disorders • Multiple Sclerosis

Risk Factors for Loss of Varicella Immunity After Pediatric Kidney Transplantation (WTC 2025) - "Pts received induction with either a lymphocyte depleting (LDA: ATG or alemtuzumab) or a non-lymphocyte depleting agent (NLDA: basiliximab or daclizumab) and maintained on mycophenolate mofetil, tacrolimus, with or without corticosteroids. Pediatric kidney Tx Pts are at risk for losing VZV immunity after Tx, with higher incidences among those who were younger at the time of Tx, on steroid-based immunosuppression, required three or more doses of VZV Vx to seroconvert, or received VZV Vx <1 yr before Tx. Post-Tx VZV serologies should be monitored to identify Pts at high risk for disseminated VZV."

Clinical • Herpes Zoster • Pediatrics • Transplantation • Varicella Zoster

Comparative Efficacy and Safety of Induction Therapy in Solid Organ Transplantation: A Systematic Review and Network Meta-Analysis (WTC 2025) - "Ranking probabilities based on the surface under the cumulative ranking curve (SUCRA) indicated that alemtuzumab (SUCRA 93.9%) exhibited the highest potential superiority in reducing the rejection rate, followed by ALG, belimumab, rATG, OKT3, daclizumab, odulimomab, basiliximab, rituximab, Lo-tact-1, and inolimomab... Alemtuzumab is the most effective therapy for reducing the rejection rate. OKT3 is the primary therapeutic option for enhancing graft survival. Basiliximab is an important therapeutic option for improving overall survival."

Retrospective data • Review • Infectious Disease • Solid Organ Transplantation • Transplantation

Let s Get Them United: In Block Reconstruction for Dual Graft Kidney Transplantation (WTC 2025) - "Donor characteristics : age 65 ± 9.6.Cause of death % - Stroke - Trauma 68.3 21.9 KDPI % 94 ±7 Remuzzi 5.8 ± 0.9 4 : 2 patients, 5 : 9 patients 6 : 16 patients 7 : 21 patients FG (ml/min) 57.2 ± 17.3 Recipient characteristics : age (median ± SD, years) 61.7 ± 10.9 Recipient sex (female male) % 48.5% / 51.5%Type of Dialysis : Peritoneal dialysis 4, hemodialysis: 44 Time on dialysis (years) 3.8 ± 3.5 Immunosuppressive regimen Daclizumab /MF/steroids /TAC 7 patients , Timog /steroids /SIROLIMUS: 6 , Timog/steroids/MF/TAC 28 Basiliximab/Belatacept/MF/GC 3 Thymoglobulin/Belatacept/MF/GC 4... Dual transplantation is a strategy to optimize organ utilization. We have decided to change our usual technique of implanting both grafts separately in the same iliac fossa to en bloc reconstruction of both kidneys separated during organ harvesting . this shortens the operative time , decreases the incision size, shortens the anastomosis times and..."

Cardiovascular • Gastroenterology • Transplantation

Identification of crucial disulfidptosis genes and regulatory biomarkers in diabetic retinopathy based on bioinformatics analysis. (PubMed, Biochem Biophys Res Commun) - "Additionally, drug-target predictions identified Bevacizumab, Daclizumab, and Palivizumab as possible therapeutic options targeting C1QA and FCGR2B. These findings establish a theoretical foundation for leveraging disulfidptosis-related biomarkers in DR diagnosis and treatment."

Biomarker • Journal • Diabetic Retinopathy • Retinal Disorders • C1QA • FCGR2B • ITGAM • SPI1 • TYROBP

Persistence of Graft Function Following Discontinuation of Immunosuppression in an Islet Transplant Recipient on Chronic GLP-1 RA Therapy (IPITA 2025) - " A 36 y/o male with a 34-year history of T1D complicated by SHE with negative stimulated C-peptide, received a total of 3 ITx (2ndITx at 1.2-months, and 3rdITx at 18.7-months) under daclizumab induction and tacrolimus-sirolimus maintenance...Nineteen years post-ITx, he received COVID-19 vaccination and was switched from dulaglutide to semaglutide... Stable graft function with acceptable metabolic control was maintained for 7-months post IS-discontinuation. GLP-1 RA therapy coincided with improvement in Treg:Tcov ratio and a reduction in %CD8 Tem cells, suggesting a favorable immunological profile. GLP-1 RA are associated with anti-inflammatory and immunomodulatory properties."

Clinical • Hypoglycemia • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Transplantation • CD8

Induction With Antithymocyte Globulin Is Associated With Decreased Mortality and PTLD in Pediatric Liver Transplantation: A UNOS Data Analysis. (PubMed, Pediatr Transplant) - "Induction with ATG is associated with decreased mortality and PTLD, though it is also associated with an increased risk of organ rejection. These results may support its use in the optimal induction regimen for pediatric liver transplantation."

Journal • Retrospective data • Cytomegalovirus Infection • Pediatrics • Transplant Rejection • Transplantation

Comprehensive analysis of SQOR involvement in ferroptosis resistance of pancreatic ductal adenocarcinoma in hypoxic environments. (PubMed, Front Immunol) - "In slide level, our deep learning model can effectively identify PDAC hypoxia levels with good performance...This study has established a hypoxia detection model of PDAC based on WSIs, providing a new tool for clinical evaluation. The study revealed a new mechanism of SQOR mediating ferroptosis resistance under hypoxia and provided a basis for targeted therapy."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • SQOR

SHORT-TERM SUBSTITUTION OF CALCINEURIN INHIBITORS (CNIS) WITH RECOMBINANT HUMANIZED ANTI-CD25 MONOCLONAL ANTIBODY (DACLIZUMAB) AS AGVHD PROPHYLAXIS IN CNIS INTOLERANT PATIENTS AFTER ALLO-HSCT (EBMT 2025) - "When CNI intolerance occurs during allo-HSCT, short-term replacement with Daclizumab can be used as an alternative to prevent aGVHD. Clinical Trial Registry: N/A"

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Infectious Disease • Nephrology • Oncology • Solid Organ Transplantation • Transplant Rejection

SHORT-TERM SUBSTITUTION OF CALCINEURIN INHIBITORS (CNIS) WITH RECOMBINANT HUMANIZED ANTI-CD25 MONOCLONAL ANTIBODY (DACLIZUMAB) AS AGVHD PROPHYLAXIS IN CNIS INTOLERANT PATIENTS AFTER ALLO-HSCT (EBMT 2025) - "When CNI intolerance occurs during allo-HSCT, short-term replacement with Daclizumab can be used as an alternative to prevent aGVHD. Clinical Trial Registry: N/A"

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Infectious Disease • Nephrology • Oncology • Solid Organ Transplantation • Transplant Rejection

Evolving Patterns of Initial RRMS Treatment in Finland (2013-2022): Insights From a Nationwide Multiple Sclerosis Register. (PubMed, Brain Behav) - "In Finland, the treatment of RRMS has shifted toward earlier diagnosis and earlier initiation of heDMTs, likely improving the prognosis of the patients."

Journal • Retrospective data • CNS Disorders • Infectious Disease • Multiple Sclerosis • Novel Coronavirus Disease

Identifying Promising Immunomodulators for Type 1 Diabetes (T1D) and Islet Transplantation. (PubMed, J Diabetes Res) - P, P1/2, P2, P2/3, P3, P4 | "FDA-approved teplizumab for Stage 2 T1D is discussed along with other immunomodulators that have been tested in Phase 3 clinical trials or higher, including otelixizumab (another anti-CD3 monoclonal antibody), daclizumab (an anti-CD25 monoclonal antibody), ladarixin (CXCR1/2 inhibitor), and antithymocyte globulin (ATG)...Several immunomodulators involved in Phase 3 clinical studies of islet transplantation are also discussed, including alemtuzumab, basiliximab, etanercept, and reparixin, some already FDA-approved for other uses...This review provides background, mechanism of action, results of completed trials, and adverse effects as well as details regarding ongoing clinical trials for each of these immunomodulators. Trial Registration: ClinicalTrials.gov identifier: NCT03875729, NCT01030861, NCT00129259, NCT00385697, NCT01280682; NCT03929601, NCT04598893, NCT05757713, NCT00678886, NCT01123083, NCT00064714, NCT00468117, NCT04628481,..."

Journal • Review • Diabetes • Immunology • Metabolic Disorders • Transplantation • Type 1 Diabetes Mellitus • CXCR1

Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis. (PubMed, Cochrane Database Syst Rev) - "The number of people with PMS with relapses is probably slightly reduced with rituximab at two years, and interferon beta-1b at three years, compared to placebo. Both drugs are also probably associated with a slightly higher proportion of withdrawals due to adverse events, as are immunoglobulins, glatiramer acetate, natalizumab, fingolimod, siponimod, and ocrelizumab; we have high confidence that this is the case with interferon beta-1a. We found only low or very low certainty evidence relating to disability progression for the included disease-modifying treatments compared to placebo, largely due to imprecision. We are also uncertain about the effect of interventions on serious adverse events, also because of imprecision. These findings are due in part to the short follow-up of the included RCTs, which lacked detection of less common severe adverse events. Moreover, the funding source of many included studies may have introduced bias into the results. Future research on..."

Clinical • Immunomodulating • Journal • Retrospective data • Review • CNS Disorders • Multiple Sclerosis

The short- and long-term outcomes of steroid-free regimen in liver transplantation (TTS 2024) - "At our hospital, the standard immunosuppressive therapy for blood group compatible liver transplantation is a combination of two drugs, calcineurin inhibitor (CNI) and steroids, or three drugs with mycophenolate mofetil (MMF) added to reduce the nephrotoxicity of CNI...Eight patients who received 1 gram of methylprednisolone only intraoperatively and one patient who received daclizumab instead of basiliximab and did not use steroids were also included in the Fr group... Steroid-free immunosuppressive therapy was able to maintain induction of immune tolerance without increasing postoperative acute rejection and de novo malignancies."

Hepatology • Infectious Disease • Oncology • Transplant Rejection • Transplantation